Dicot AB publishes the Annual Report 2022
Press release: Uppsala, Sweden, April 28, 2023. The annual report of Dicot AB (publ) for 2022 has been published today and is available on www.dicot.se and as an attachment to this press release. Our financial reports are available on www.dicot.se/en/investor-relations/reports-and-issues/
For further information, please contact:
Elin Trampe, CEO
Phone: +46 739 80 14 08
E-mail: [email protected]
Björn Petersson, CFO
Phone: +46 761 09 00 00
E-mail [email protected]
About Dicot AB
Dicot is developing the drug candidate LIB-01, which will be a potency agent to better treat erectile dysfunction and premature ejaculation. The ambition is to create a drug with significantly longer effect and far fewer side effects, compared to current available drugs. Today, over 500 million men suffer from these sexual dysfunctions and the market is valued at USD 7 billion. Dicot's strategy is to develop LIB-01 under own auspices until phase 2a studies and thereafter in partnership with larger, established pharmaceutical companies, finance and develop LIB-01 further to a registered pharmaceutical on the world market.
Dicot is listed on Spotlight Stock Market and has approximately 4,100 shareholders. For more information, please visit www.dicot.se.
Om Dicot Pharma
Dicot utvecklar ett modernt potensläkemedel som ska behandla erektionssvikt och för tidig utlösning bättre än befintliga preparat.
Handelsinformation
IR-Kontakt
